الفهرس 
Formulation and Evaluation of different Niosomes and Bilosomes formulae of a Certain Drug
Table of contentOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Migraine attack is a troublesome physiological condition associated with throbbing, intense headache, in one half of the head. Zolmitriptan is a potent second-generation triptan, prescribed for patients with migraine attacks, with or without an aura, and cluster headaches. The absolute bioavailability of zolmitriptan is about 40 % for oral administration; due to hepatic first metabolism. Transdermal administration would circumvent the pre-systemic metabolism thus increasing the bioavailability of zolmitriptan.. Thus, the aim of this work is to explore the potential of niosomes and bilosomes for effective and enhanced transdermal delivery of zolmitriptan. The developed formulations were statistically optimized by factors, and levels using full factorial and Box{u2013}Behnken designs and were evaluated for vesicle size, zeta potential, entrapment efficiency and in-vitro release. The optimized bilosomes and niosomes were evaluated for ex-vivo permeation study. Stratum corneum (SC) has a selective function for most drugs because of its underlying capillary network. Edge activators (EAs) such as bile salts endow the nanovesicles ultraflexibility properties to transpass SC by high self-optimizing deformability. Bilosomes were prepared by thin film hydration (TFH) technique according to full 31.22 factorial design to select the optimal formulation using DesignExpert-10® software. The optimal bilosomal nanovesicles (B2) showed nanosized vesicles (110.8 nm) and 96.6 % entrapment efficiency (%EE) compared to niosomal formulation Fn (223.2nm; 81.6% respectively). Ex-vivo permeation studies revealed that bilosomal B2 exhibited superior permeation compared to niosomal formulation(Fn)